RxDoctor Payments Data

Christopher Thompson, MD

Family Medicine · Smyrna, TNNPI 1194710889

Payments from drug & device makers

$7,804in general payments, 2019–2025

Across 535 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$861
  • AbbVie$680
  • Amgen$633
  • Pfizer$632
  • AstraZeneca$571
  • Lilly USA, LLC$487
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,51396%
  • Education$2904%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,804 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$34,569
Medicare patients
51
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$69,053
EliquisApixaban56$58,353
MounjaroTirzepatide26$26,527
Soliqua 100-33Insulin Glargine/Lixisenatide27$24,504
Repatha SureclickEvolocumab25$21,124
Xigduo XrDapaglifloz Propaned/Metformin18$18,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$15,792
Valsartan110$6,546
NexlizetBempedoic Acid/Ezetimibe12$4,670
SynthroidLevothyroxine Sodium51$4,500
Testosterone16$3,349
Duloxetine Hcl63$1,418
Atorvastatin Calcium74$1,239
Rosuvastatin Calcium98$1,235
Pravastatin Sodium47$897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$861$69,05358 claims
PfizerEliquis$632$58,35356 claims
Lilly USA, LLCMounjaro$487$26,52726 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$322$24,50427 claims
GSKTrelegy Ellipta$442$15,79211 claims
Esperion Therapeutics, Inc.Nexlizet$151$4,67012 claims
AbbVieSynthroid$680$4,50051 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$73077 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Smyrna

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →